logo-loader
viewANGLE PLC

Scientists make major breakthrough with ANGLE’s Parsortix liquid biopsy system

It had previously been thought that brain cancers couldn’t be traced by ANGLE’s Parsortix system, but a team of Scientists has disproved that theory

blood
Parsortix works by detecting and capturing circulating tumour cells in the bloodstream

Researchers have shown that ANGLE PLC’s (LON:AGL) Parsortix liquid biopsy system can be used to identify people with glioblastoma – an aggressive type of brain cancer.

Parsortix detects and captures circulating tumour cells (CTCs), which provide the tell-tale signs of cancer and their capture can allow doctors to more accurately assess treatment options.

READ: ANGLE on track to conclude FDA study by year-end

It had previously been thought that clusters of CTCs in brain cancers would not pass through the blood-brain barrier meaning ANGLE’s system wouldn’t have been able to detect them.

But a team of scientists from the University of Basel in Switzerland has disproved that theory, showing that as well as singular CTCs, clusters of CTCs will pass through the blood-brain barrier and can be harvested for analysis using the Parsortix system.

“The glioblastoma work is a further example of ground breaking research being undertaken by a Parsortix customer in addition to ANGLE's own efforts to commercialise the Parsortix system,” said chief executive Andrew Newland.

“University of Basel and their collaborators are working on the application of this approach for the treatment of glioblastoma patients and we look forward to reporting further developments in due course.”

Shares rose 5.2% in early deals on Tuesday to 48.9p.

Quick facts: ANGLE PLC

Price: 61 GBX

AIM:AGL
Market: AIM
Market Cap: £105.38 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ANGLE PLC submits its flagship Parsortix liquid biopsy diagnostic to the FDA

ANGLE PLC (LON:AGL) (OTCQX:ANPCY) CEO Andrew Newland tells Proactive the company has submitted its patent-protected, flagship Parsortix liquid biopsy diagnostic for clearance to the FDA.  Newland says this is a tremendous opportunity for ANGLE, as he says ANGLE is the first company to...

on 30/10/19

2 min read